Cancer Patents (Class 436/813)
-
Patent number: 9017957Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.Type: GrantFiled: May 1, 2007Date of Patent: April 28, 2015Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro KitamuraInventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
-
Patent number: 8980637Abstract: A method for the parallel identification of one or more metabolite species within a biological sample is provided. The method comprises producing a first spectrum by subjecting the sample to a nuclear magnetic resonance analysis, the first spectrum containing individual spectral peaks representative of the one or more metabolite species contained within the sample; producing a second spectrum by subjecting the sample to a mass spectrometry analysis, the spectrum containing individual spectral peaks representative of the one or more metabolite species contained within the sample; subjecting each of the individual spectral peaks to a statistical pattern recognition analysis to identify the one or more metabolite species contained within the sample; and identifying the one or more metabolite species contained within the sample by analyzing the individual spectral peaks of the mass and nuclear magnetic resonance spectra.Type: GrantFiled: October 3, 2008Date of Patent: March 17, 2015Assignee: Purdue Research FoundationInventors: Daniel M. Raftery, Zhengzheng Pan, Haiwei Gu
-
Patent number: 8945929Abstract: Provided are a marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a substance in a metabolic pathway in which L-phenylalanine and/or N,N-dimethyl glycine are/is involved.Type: GrantFiled: January 30, 2009Date of Patent: February 3, 2015Assignees: Keio University, Kabushiki Kaisha Yakult HonshaInventors: Yusuke Tanigawara, Mitsuhiro Watanabe, Eri Arita, Akito Nishimuta, Yasuko Yamayoshi, Takeshi Matsuzaki, Shinji Sugimoto
-
Patent number: 8900881Abstract: The present invention relates to a quantitative assay device and a method for the determination of an analyte, based on a test strip, which contains a porous test membrane allowing for capillary flow of the analyte and complexes of the analyte, a porous upstream membrane in fluid connection with the test membrane and a porous downstream membrane in fluid connection with the test membrane, wherein the test membrane contains two bands having deposited on there high and low concentrations of different calibrator agents and a test band capable of reacting with conjugated analyte complexes giving rise to a measurable signal.Type: GrantFiled: September 12, 2011Date of Patent: December 2, 2014Inventor: Jin Po Lee
-
Patent number: 8785202Abstract: The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer.Type: GrantFiled: February 18, 2010Date of Patent: July 22, 2014Assignee: CytImmune Sciences, Inc.Inventors: Lawrence Tamarkin, Giulio F. Paciotti
-
Patent number: 8765392Abstract: The present invention relates to methods and kits for diagnosing, ascertaining the clinical course of myelodysplastic syndrome (MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS.Type: GrantFiled: January 11, 2013Date of Patent: July 1, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: Jonni Moore, Sundhu Cherian, Adam Bagg
-
Patent number: 8753892Abstract: The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for prostate cancer, and the use of PDE4D7 as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs.Type: GrantFiled: May 11, 2010Date of Patent: June 17, 2014Assignee: Koninklijke Philips N.V.Inventors: Ralf Hoffmann, Miles Douglas Houslay, David James Peter Henderson
-
Patent number: 8685666Abstract: This invention provides antibodies immunologically specific for human ARL-1 (also referred to AKR1B10), a species of the aldo-keto reductase superfamily of proteins. The invention also provides methods of making and methods of using said antibodies.Type: GrantFiled: January 31, 2011Date of Patent: April 1, 2014Assignee: The Board of Trustees of Southern Illinois UniversityInventor: Deliang Cao
-
Patent number: 8679848Abstract: A collection device for use in connection with off-device testing of collected samples. The device includes a first panel having one or more apertures for receiving samples, a second panel opposite the first panel, and a removable tab having a first portion and a second portion. The first portion is aligned with at least one of apertures on the first panel and constructed such that depositing the sample through the at least one aperture causes the sample to be directly deposited on the first portion of the tab, and the second portion includes a sample-free grasping area accessible from an exterior of the device for removing the tab. A method of obtaining a sample is also disclosed.Type: GrantFiled: June 3, 2013Date of Patent: March 25, 2014Assignee: Immunostics, Inc.Inventor: Vincent P. LaStella
-
Patent number: 8603765Abstract: The present invention provide reagents and methods of using the reagents, for example, on automated staining devices, that facilitate detection of two or more antigens in a sample simply and efficiently.Type: GrantFiled: October 27, 2009Date of Patent: December 10, 2013Assignee: Biocare Medical, LLC.Inventor: David Tacha
-
Patent number: 8592224Abstract: A biochip for diagnostic purposes comprises a sample carrier made of a solid matrix, on the surface of said sample carrier is bound the sample material to be analysed which originates from a biological organism.Type: GrantFiled: November 20, 2007Date of Patent: November 26, 2013Assignee: Bioref GmbHInventor: Hans-Jurgen Staab
-
Patent number: 8568994Abstract: The invention discloses a method of prenatal diagnosis comprising the step of isolating exosomes from an isolated fluid, wherein the exosomes are identified by biomarker detection. Furthermore, the invention discloses the isolation of exosomes from an isolated fluid and the use of a biomarker, particularly CD24 to isolate exosomes from an isolated fluid.Type: GrantFiled: August 1, 2008Date of Patent: October 29, 2013Assignee: DKFZ Deutsches Krebsforschungszentrum, Stiftung des Offentlichen RechtsInventors: Peter Altevogt, Sascha Keller
-
Patent number: 8563249Abstract: Compositions and methods that use the body's natural secretory immune system in a new way against steroid hormone responsive tumors of the breast and prostate, as well as other glandular/mucus epithelial tissues such as colon, ovary, endometrium, kidney, bladder, stomach, pancreas and secretory pituitary gland are provided. Also provided are new ways of identifying carcinogenic, or potentially carcinogenic, bacteria in a tissue or body fluid to provide better anti-cancer therapies and preventatives than have been available previously.Type: GrantFiled: May 20, 2011Date of Patent: October 22, 2013Assignee: Signe BioPharma Inc.Inventor: David A. Sirbasku
-
Patent number: 8551786Abstract: Systems and methods for enhancing fluorescent detection of target molecules in a test sample are for use with an irradiating device. First fluorophores are provided for absorption of EMF radiation, and emission of a first signal. Second fluorophores are provided for partial absorption of the first signal, and emission of a second signal distinguishable from the first signal. The fluorophores are combined with the test sample, and secured to the target molecules and relative to one another. After the first fluorophores receive the EMF radiation from the irradiating device, the first signal is detected, together with the second spectral signal if the target molecules are present in the test sample.Type: GrantFiled: July 9, 2008Date of Patent: October 8, 2013Assignee: FIO CorporationInventors: Warren Che Wor Chan, Travis Leon Jennings, Jesse M. Klostranec
-
Patent number: 8512960Abstract: This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.Type: GrantFiled: September 26, 2008Date of Patent: August 20, 2013Assignee: A&G Pharmaceutical, Inc.Inventor: Ginette Serrero
-
Patent number: 8486657Abstract: It is disclosed herein that antibodies specific for preproproteins or preproteins, which are synthesized by certain types of cells or tissues, can be used in immunohistochemistry assays to discriminate between the intracellular component of the protein (including the preproprotein, preprotein and/or proprotein forms of the protein) from the secreted component of the same protein. Accordingly, provided herein is an immunohistochemical method for specific detection of the intracellular form of a protein in a biological sample using an antibody specific for the preproprotein or preprotein form of the protein. In particular examples, the protein is albumin or an immunoglobulin light chain. Also disclosed herein are preproprotein-specific ore preprotein-specific antibodies that can be used to detect specific cell types, tissue lesions or other pathological foci and metastases by IHC. In particular, antibodies that specifically bind human preproalbumin, but do not bind the secreted form of albumin are disclosed.Type: GrantFiled: March 22, 2010Date of Patent: July 16, 2013Inventors: Xiaohong Cai, Thomas Cai
-
Patent number: 8455200Abstract: The present invention relates to a method of detecting the presence of cancer by measuring the level of enzyme activity and autoantibodies in the blood of an individual. In particular the present invention relates to methods for measurement of activated cAMP-dependent protein kinase A (PKA) activity and antibodies to PKA, a kit for activated PKA activity measurement, and the use of the measured levels of these analytes for determining the presence of cancer.Type: GrantFiled: October 14, 2010Date of Patent: June 4, 2013Assignee: Traxxsson, LLCInventors: Robert Puskas, Douglas Held
-
Patent number: 8455263Abstract: The present invention relates to an assay device and a method for using such for the quantitative determination of an analyte, based on a test strip, which contains a porous test membrane allowing for capillary flow of the analyte and complexes of the analyte, a porous upstream membrane in fluid connection with the test membrane and a porous downstream membrane in fluid connection with the test membrane, wherein the test membrane contains a test site having immobilized thereon a ligand capable of reacting with the analyte and binding such to the test site, and two standard band sites having immobilized thereon known high and low concentrations of a calibrator agent capable of reacting with a label conjugate and binding such to the standard sites, wherein the upstream membrane has a site for the application of a sample to be analyzed, and has a site downstream from the sample application site for depositing label conjugates capable of reacting with the analyte and label conjugates capable of reacting with theType: GrantFiled: December 30, 2008Date of Patent: June 4, 2013Inventor: Jin Po Lee
-
Patent number: 8399202Abstract: Novel immuno-interactive fragments of the ?C portion of a mammalian inhibin ? subunit, together with their variants and derivatives, produce antigen-binding molecules that are interactive with the ?C portion, and which are chemically well defined and which can be produced in commercially significant quantities. The antigen-binding molecules of the invention can be used for the detection of a mammalian inhibin and for the treatment and/or prevention of conditions associated with aberrant levels of a mammalian inhibin.Type: GrantFiled: March 30, 2009Date of Patent: March 19, 2013Assignee: Prince Henry's Institute of Medical ResearchInventors: David Mark Milne-Robertson, Peter Gordon Stanton, Nicholas Francis Cahir
-
Patent number: 8377649Abstract: The present invention relates to methods and kits for diagnosing, ascertaining the clinical course of myelodysplastic syndrome (MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS.Type: GrantFiled: February 1, 2011Date of Patent: February 19, 2013Assignee: The Trustees of the University of PennsylvaniaInventors: Jonni Moore, Sindhu Cherian, Adam Bagg
-
Patent number: 8343440Abstract: A cancer cell separating apparatus includes: a flow channel including an antibody fixation area having antibodies which bind specifically to cancer cells fixed thereon, wherein the cancer cells and non-cancer cells are separated using a difference in velocity of movement between the cancer cells and the non-cancer cells in cell slurry introduced into the flow channel.Type: GrantFiled: March 23, 2010Date of Patent: January 1, 2013Assignee: Seiko Epson CorporationInventor: Satomi Yoshioka
-
Patent number: 8288087Abstract: The present invention provides a method for determining a response of a mammalian subject having melanoma tumor cells to treatment with a melanoma inhibitory agent. In one aspect, the method comprises (a) determining a first concentration of melanoma inhibitory activity protein (MIA) in a first biological sample taken from the mammalian subject before treatment with the melanoma inhibitory agent; (b) determining a second concentration of MIA in a second biological sample from the mammalian subject taken after treatment with the melanoma inhibitory agent; and (c) comparing the first and second concentrations of MIA, wherein a decrease in the second concentration of MIA measured in the second biological sample as compared to the first concentration of MIA measured in the first biological sample indicates a positive response to the treatment with the melanoma inhibitory agent.Type: GrantFiled: July 26, 2007Date of Patent: October 16, 2012Assignee: Novartis AGInventors: Nguyen Tan, Eleni Venetsanakos, Michel Faure, Carla Heise
-
Patent number: 8247188Abstract: The disclosed invention relates to monoclonal antibodies (MAbs) which recognize human fatty acid synthase (hFAS) and are distinct from previously known anti-hFAS antibodies. Compositions, devices and kits comprising the MAbs are provided along with methods of using the MAbs in a variety of applications.Type: GrantFiled: August 17, 2006Date of Patent: August 21, 2012Assignee: Fasgen Diagnostics, LLCInventors: Susan Medghalchi, Jennifer L. Aldrich
-
Patent number: 8114604Abstract: A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigen. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient.Type: GrantFiled: December 10, 2007Date of Patent: February 14, 2012Assignee: OncImmune Ltd.Inventors: John F. R. Robertson, Catherine R. L. Graves, Michael R. Price, Frances Margaret Price, legal representative
-
Patent number: 8071322Abstract: The invention provides a method of identifying an antigen that is present in different amounts in two different samples. In general, the methods involve generating a first and second distinguishably labeled population of antibodies that reactive to the two samples, contacting the first and second labeled populations of antibodies with a plurality of antigens; and identifying any resultant antigens that are differentially bound by the first and second populations of antibodies. The antigens may be on the surface of cells e.g., animal cells, or on a solid support. Once identified, the nucleic acid encoding an antigen of interest may be identified and sequenced to reveal the identity of the antigen of interest. Kits for performing the methods are also provided. The methods find most use in medical and research applications, in particular, for identifying cell surface targets for immunotherapy and drug discovery.Type: GrantFiled: November 10, 2003Date of Patent: December 6, 2011Assignee: Epitomics, Inc.Inventor: Dongxiao Zhang
-
Patent number: 8021837Abstract: Disclosed are new methods comprising the use of in situ hybridization to detect abnormal nucleic acid sequence copy numbers in one or more genomes wherein repetitive sequences that bind to multiple loci in a reference chromosome spread are either substantially removed and/or their hybridization signals suppressed. The invention termed Comparative Genomic Hybridization (CGH) provides for methods of determining the relative number of copies of nucleic acid sequences in one or more subject genomes or portions thereof (for example, a tumor cell) as a function of the location of those sequences in a reference genome (for example, a normal human genome). The intensity(ies) of the signals from each labeled subject nucleic acid and/or the differences in the ratios between different signals from the labeled subject nucleic acid sequences are compared to determine the relative copy numbers of the nucleic acid sequences in the one or more subject genomes as a function of position along the reference chromosome spread.Type: GrantFiled: February 24, 2006Date of Patent: September 20, 2011Assignee: The Regents of the University of CaliforniaInventors: Daniel Pinkel, Joe W Gray, Anne Kallioniemi, Ollie-Pekka Kallioniemi, Frederic Waldman, Masaru Sakamoto
-
Patent number: 7935520Abstract: Methods and compositions are provided for detecting biomolecular interactions. The use of labels is not required and the methods can be performed in a high-throughput manner. The invention also provides optical devices useful as narrow band filters.Type: GrantFiled: June 25, 2009Date of Patent: May 3, 2011Assignee: SRU Biosystems, Inc.Inventors: Brian T. Cunningham, Jane Pepper, Bo Lin, Peter Li, Homer Pien, Jean Qiu
-
Patent number: 7879569Abstract: The present invention relates to methods and kits for diagnosing, ascertaining the clinical course a of myelodysplastic syndrome(MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides method and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS.Type: GrantFiled: November 7, 2005Date of Patent: February 1, 2011Assignee: The Trustees of the University of PennsylvaniaInventors: Jonni Moore, Sindhu Cherian, Adam Bagg
-
Patent number: 7863012Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.Type: GrantFiled: February 17, 2004Date of Patent: January 4, 2011Assignee: Veridex, LLCInventors: Galla Chandra Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon W. M. M. Terstappen, Shawn Mark O'Hara, Steven Gross
-
Patent number: 7820447Abstract: The present invention relates to novel sequences for use in diagnosis and treatment of carcinomas, especially lymphoma carcinomas. In addition, the present invention describes the use of novel compositions for use in screening methods.Type: GrantFiled: December 26, 2001Date of Patent: October 26, 2010Assignee: Sagres Discovery Inc.Inventors: David W. Morris, Eric K. Engelhard
-
Patent number: 7767393Abstract: The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications.Type: GrantFiled: January 31, 2006Date of Patent: August 3, 2010Assignee: The Regents of the University of MichiganInventors: Arul M. Chinnaiyan, Mark A. Rubin, Arun Sreekumar
-
Patent number: 7615358Abstract: A method for determining the concentration of vital epithelial tumor cells in a body fluid is disclosed. The method comprises obtaining from the body fluid of a test subject a test specimen, labeling the epithelial tumor cells contained in said test specimen, applying the test specimen to a support, where the epithelial tumor cells adhere and identifying vital cells of the adhering epithelial tumor cells by means of their morphology. The method does not comprise an enrichment of epithelial tumor cells by means of binding to paramagnetic or magnetic particles and applying a magnetic force to the particles.Type: GrantFiled: April 10, 2007Date of Patent: November 10, 2009Inventors: Ulrich Pachmann, Katharina Pachmann
-
Patent number: 7605003Abstract: The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.Type: GrantFiled: August 5, 2003Date of Patent: October 20, 2009Assignees: The Johns Hopkins University, Vermillion, Inc.Inventors: Daniel W. Chan, Zhen Zhang, Eric Fung, Xiao-Ying Meng
-
Patent number: 7569675Abstract: A lagomorph derived monoclonal antibody for recognizing the progesterone receptor (PR) (clone SP2) with immunohistochemistry and methods for creating such an antibody are disclosed. No need of target retrieval in immunohistochemistry is their prominent advantage compared to currently available PR antibody. Furthermore, the very low background when the lagomorph derived monoclonal antibody is used in immunohistochemistry is also impressive. The immunohistochemistry comparative study with about fifty clinical specimens showed that the new PR antibody (clone SP2) antibody had favorable results when compared to mouse monoclonal antibody PR (clone 1A6), the best one in the current market. The PR antibody may prove of great value in the assessment of PR status in human breast cancer. Humanized versions of the PR antibody may provide therapeutic benefits.Type: GrantFiled: September 11, 2002Date of Patent: August 4, 2009Assignee: Spring Bioscience CorporationInventors: Haiying Xia, Zhida Huang
-
Patent number: 7541160Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA method and kits for VEGF as an antigen were developed to detect VEGF levels in biological samples from animal models and human patients and are used as a diagnostic/prognostic index.Type: GrantFiled: November 1, 2004Date of Patent: June 2, 2009Inventors: David Tai Wai Fei, Kristen Tomita
-
Patent number: 7524681Abstract: The present invention relates to a method for determining the condition of a biological fluid by recording the IR spectrum of a sample of the biological fluid. To this end, the biological fluid can be examined in its native form. The method of the invention is usable, for example, for detecting pathological conditions in organisms.Type: GrantFiled: January 22, 2002Date of Patent: April 28, 2009Inventors: Andreas Wolf, Ralf Masuch, Robert Seidel
-
Patent number: 7511123Abstract: Novels immuno-interactive fragments of the (alpha)C portion of a mammalian inhibin alpha subunit are disclosed, together with their variants and derivatives for producing antigen-binding molecules that are interactive with said (alpha)C portion, which are chemically well defined and which can be produced in commercially significant quantities. The antigen-binding molecules of the invention can be used for the detection of a mammalian inhibin and for the treatment and/or prevention of conditions associated with aberrant levels of a mammalian inhibin.Type: GrantFiled: April 18, 2002Date of Patent: March 31, 2009Assignee: Prince Henry's Institute of Medical ResearchInventors: David Mark Milne-Robertson, Peter Gordon Stanton, Nicholas Francis Cahir
-
Patent number: 7473564Abstract: The invention concerns a kit for the detection of protein ESM-1 in a sample, comprising: a) a first antibody specifically binding to the N-terminal region of protein ESM-1 contained between the amino acid in position 20 and the amino acid in position 78 of the amino acid sequence of this protein; and b) a second antibody specifically binding to the C-terminal region contained between the amino acid in position 79 and the amino acid in position 184 of the amino acid sequence of protein ESM-1.Type: GrantFiled: November 8, 2001Date of Patent: January 6, 2009Assignees: Institut Pasteur de Lille, Institut National de la Sante et de la Recherche MedicaleInventors: Philipp Lassalle, David Bechard, André-Bernard Tonnel
-
Patent number: 7462491Abstract: Serum cav-1 is disclosed as a biomarker for prostate cancer that has the power to differentiate between prostate cancer and BPH patients.Type: GrantFiled: September 15, 2004Date of Patent: December 9, 2008Assignee: Baylor College of MedicineInventor: Timothy C. Thompson
-
Patent number: 7455964Abstract: The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases.Type: GrantFiled: January 17, 1997Date of Patent: November 25, 2008Assignees: The Hospital for Sick Children, The Regents of the University of CaliforniaInventors: Joe W. Gray, Colin Conrad Collins, Soo-in Hwang, Tony Godfrey, David Kowbel, Johanna Rommens
-
Patent number: 7452727Abstract: The present invention relates to an automatable method for the improved diagnosis of pathologically altered cells by simultaneously staining at least two different molecular markers, which exhibit a change in gene expression which is disease-associated, in a cell or constituent regions of a tissue sample by means of using combinations of antibodies and accrediting signal intensities.Type: GrantFiled: December 17, 2001Date of Patent: November 18, 2008Assignee: Siemens Healthcare Diagnostics IncInventors: Guido Hennig, Ralph Wirtz, Kerstin Bohmann, Birge Schopper
-
Patent number: 7387772Abstract: The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer.Type: GrantFiled: April 5, 2002Date of Patent: June 17, 2008Assignee: Immunimedics, Inc.Inventors: Hans J. Hansen, David M. Goldenberg
-
Patent number: 7371562Abstract: Methods and compositions are provided for detecting biomolecular interactions. The use of labels is not required and the methods can be performed in a high-throughput manner. The invention also provides optical devices useful as narrow band filters.Type: GrantFiled: August 10, 2005Date of Patent: May 13, 2008Assignee: SRU Biosystems, Inc.Inventors: Brian T. Cunningham, Jane Pepper, Bo Lin, Peter Li, Jean Qiu, Homer Pien
-
Patent number: 7332290Abstract: The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. The present invention also provides novel markers useful for the diagnosis, characterization, and treatment of prostate cancers. In particular, the present invention provides methods and compositions for the detection of ?-methylacyl-CoA racemase (AMACR) in the urine as a marker for prostate cancer detection.Type: GrantFiled: July 30, 2004Date of Patent: February 19, 2008Assignee: The Regents of the University of MichiganInventors: Mark A. Rubin, Arul M. Chinnaiyan, Bharathi Laxman, Arun Sreekumar
-
Patent number: 7282345Abstract: Disclosed are methods and compositions for identifying malignant tumors that overexpress the c-erbB-2 oncogene. Assays useful for diagnosis and prognosis of neoplastic disease are provided which detect the external domain of c-erbB-2, the glycoprotein gp75 and quantitate the level of gp75 in the biological fluids of mammals carrying a tumor burden. Further disclosed are recombinant, synthetically and otherwise biologically produced novel proteins and polypeptides which are encoded by the external domain DNA sequence of the c-erbB-2 oncogene (the gp75 gene) or fragments thereof. Such gp75 proteins and polypeptides are useful as vaccines, therapeutically in the treatment of cancer either alone or in combination with chemotherapeutic agents. Also disclosed are antibodies to such gp75 proteins and polypeptides which are useful diagnostically and therapeutically. Still further disclosed are test kits embodying the assays of this invention.Type: GrantFiled: November 29, 1993Date of Patent: October 16, 2007Assignee: Schering AGInventors: Miriam E. C. Hancock, John J. Monahan, Beatrice Claudia Langton
-
Patent number: 7262058Abstract: The amount of lipid associated sialoprotein (LSP) in body fluids such as cerebrospinal fluid, peritoneal fluid, pleural fluid, bronchial washings, saliva and sputum samples, may be determined by a method which may be automated, involving the following steps to be performed on the sample: adding a mixture of a chlorinated lower alkyl alcohol; centrifuging to yield a substantially clear upper phase; recovering the upper phase and adding to it a protein precipitating agent; mixing the resulting admixture; recovering the resulting precipitate; washing the precipitate with saline solution; centrifuging to recover the precipitate; dissolving the precipitate in water; mixing; adding to the resulting mixture an hydrolysis agent; heating; and determining the amount of lipid associated sialoprotein present by determining the optical density of the sample.Type: GrantFiled: March 9, 2001Date of Patent: August 28, 2007Inventor: Nonda Katopodis
-
Method for probabilistically classifying tissue in vitro and in vivo using fluorescence spectroscopy
Patent number: 7236815Abstract: Fluorescence spectral data acquired from tissues in vivo or in vitro is processed in accordance with a multivariate statistical method to achieve the ability to probabilistically classify tissue in a diagnostically useful manner, such as by histopathological classification. The apparatus includes a controllable illumination device for emitting electromagnetic radiation selected to cause tissue to produce a fluorescence intensity spectrum. Also included are an optical system for applying the plurality of radiation wavelengths to a tissue sample, and a fluorescence intensity spectrum detecting device for detecting an intensity of fluorescence spectra emitted by the sample as a result of illumination by the controllable illumination device. The system also include a data processor, connected to the detecting device, for analyzing detected fluorescence spectra to calculate a probability that the sample belongs in a particular classification.Type: GrantFiled: October 17, 2003Date of Patent: June 26, 2007Assignee: The Board of Regents of the University of Texas SystemInventors: Rebecca Richards-Kortum, Nirmala Ramanujam, Anita Mahadevan-Jansen, Michele Follen, Urs Utzinger -
Patent number: 7223842Abstract: This invention relates to nucleic acid, or fragments thereof, encoding the retinoblastoma polypeptide, the retinoblastoma polypeptide itself, methods of detecting a defective retinoblastoma gene in human patients, and methods of treating these patients.Type: GrantFiled: June 8, 1994Date of Patent: May 29, 2007Assignees: Massachusetts Eye and Ear Infirmary, Whitehead InstituteInventors: Thaddeus P. Dryja, Stephen Friend
-
Patent number: 7202334Abstract: Compositions and methods for the therapy and diagnosis of cancer, such as ovarian cancer, are disclosed. Compositions may comprise one or more ovarian carcinoma proteins, immunogenic portions thereof, polynucleotides that encode such portions or antibodies or immune system cells specific for such proteins. Such compositions may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Methods are further provided for identifying tumor antigens that are secreted from ovarian carcinomas and/or other tumors. Polypeptides and polynucleotides as provided herein may further be used for the diagnosis and monitoring of ovarian cancer.Type: GrantFiled: August 10, 2000Date of Patent: April 10, 2007Assignee: Corixa CorporationInventors: Jennifer L. Mitcham, Gordon E. King, Paul A. Algate, Steven P. Fling, Marc W. Retter, Gary R. Fanger, Steven G. Reed
-
Patent number: 7192698Abstract: Method and kits are provided for the detection and diagnosis of metastatic disease. More particularly, the methods and kits employ compounds that can detect EphA2, a specific epithelial cell tyrosine kinase that is overexpressed in metastatic tumor cells. In one embodiment the compound is an antibody capable of binding to an epitope of EphA2.Type: GrantFiled: August 17, 2000Date of Patent: March 20, 2007Assignee: Purdue Research FoundationInventors: Michael S. Kinch, Nicole D. Zantek